Integra LifeSciences Holdings Corporation
IARTNASDAQHealthcare● Active
$16.91
$-0.08(-0.46%)
Market Cap$1.3B
P/E Ratio—
52W High$17.42
52W Low$8.7
Integra LifeSciences Holdings Corporation (IART) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IART · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B |
| Cost of Revenue | $0.79B | $0.73B | $0.66B | $0.59B | $0.60B |
| Gross Profit | $0.85B | $0.88B | $0.88B | $0.97B | $0.94B |
| Gross Margin %(computed) | 51.69% | 54.77% | 57.39% | 62.29% | 61.24% |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.12B | $0.10B | $0.10B | $0.09B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.78B | $0.85B | $0.77B | $0.73B | $0.75B |
| Operating Income | $0.07B | $0.03B | $0.11B | $0.24B | $0.20B |
| Operating Margin %(computed) | 4.18% | 1.76% | 7.23% | 15.34% | 12.79% |
| Interest Income | $0.02B | $0.02B | $0.02B | $0.01B | $0.01B |
| Interest Expense | $0.09B | $0.07B | $0.05B | $0.05B | $0.05B |
| Income Before Tax | ($0.56B) | ($0.02B) | $0.08B | $0.21B | $0.21B |
| Income Tax Expense | ($0.05B) | ($0.01B) | $0.01B | $0.03B | $0.05B |
| Net Income | ($0.52B) | ($0.01B) | $0.07B | $0.18B | $0.17B |
| Net Margin %(computed) | -31.58% | -0.43% | 4.39% | 11.59% | 10.96% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.73 | $-0.09 | $0.87 | $2.18 | $2.00 |
| Wtd Avg Shares | 0.08B | 0.08B | 0.08B | 0.08B | 0.08B |
| EBITDA | ($0.33B) | $0.19B | $0.26B | $0.38B | $0.37B |
| EBITDA Margin %(computed) | -19.95% | 12.00% | 16.60% | 24.69% | 23.75% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Integra LifeSciences Holdings Corporation data
About Integra LifeSciences Holdings Corporation (IART) Income Statement
Integra LifeSciences Holdings Corporation (IART) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IART reported revenue of $1.64B, gross profit of $0.85B (gross margin 51.69%), and net income of ($0.52B) — a net profit margin of -31.58%.
Frequently asked questions
IART · 4 questionsIntegra LifeSciences Holdings Corporation (IART) reported revenue of $1.64B for 2025, up 1.5% year-over-year.
IART revenueIART salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08